Time: 8 p.m. to 10 p.m.
Agenda: To discuss research mechanisms and infrastructure needs.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Robert Baughman, MD, Associate Director for Technology Development, National Institute of Neurological, Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2137, MSC 9527, Bethesda, MD 20892–9527, (301) 496–1779.

Name of Committee: National Advisory Neurological Disorders and Stroke Council Clinical Trials Subcommittee.
Date: February 12, 2004.
Open: 8 a.m. to 8:30 a.m.
Agenda: To discuss clinical trials policy.
Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.
Closed: 8:30 a.m. to 10 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.
Contact Person: John Marler, MD, Associate Director for Clinical Trials, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2216, Bethesda, MD 20892, (301) 496–9135, *jm137@nih.gov.*

Name of Committee: National Advisory Neurological Disorders and Stroke Council Training and Career Development Subcommittee.
Date: February 12, 2004.
Time: 8 a.m. to 10 a.m.
Agenda: To discuss the training programs of the Institute.
Place: National Institutes of Health, Building 31, 31 Center Drive, A Wing, Conference Room 8A28, Bethesda, MD 20892.
Contact Person: Henry Khachaturian, PhD, Training and Special Programs Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Suite 2154, MSC 9527, Bethesda, MD 20892–9527, (301) 496–4188, *hk11b@nih.gov.*

Name of Committee: National Advisory Neurological Disorders and Stroke Council.
Date: February 12–13, 2004.
Open: February 12, 2004, 10:30 a.m. to 3:30 p.m.
Agenda: Report by the Director, NINDS; Report by the Director, Division of Extramural Research; Overview of the NINDS Intramural Program; scientific presentation, and other administrative and program developments.
Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.
Closed: February 12, 2004, 3:30 p.m. to 5 p.m.
Agenda: To review and evaluate the Division of Intramural Research Board of Scientific Counselors' reports.
Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.
Closed: February 13, 2004, 8 a.m. to 11 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.
Contact Person: Constance W. Atwell, PhD, Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892–9531, (301) 496–9248.

In the interest of security, NIH has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

Information is also available on the Institute's/Center's Home page: *www.ninds.nih.gov,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 9, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–1019 Filed 1–15–04; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method of Treating Cancer in Humans Using IL–21

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patent Application 60/368,438 (re-filed), PCT Patent Application No. PCT/US03/09707, filed March 27, 2003 (DHHS ref. E–137–2002/0–PCT–02), entitled ''Method of Treating Cancer in Humans,'' to Actis Biologics, Inc., which is located in Livermore, California. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics for the treatment of cancer via use of IL–21 with the company's proprietary Viral Vector delivery system.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 16, 2004, will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: George G. Pipia, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; telephone: (301) 435–5560; facsimile: (301) 402–0220; e-mail: *pipiag@mail.nih.gov.*

SUPPLEMENTARY INFORMATION: The primary technology describes the use of IL–21 for cancer therapy and/or cancer prevention. When compared to similar cytokines, IL–21 has shown substantial anticancer activity and reduced toxicity in murine models.

IL–21 belongs to the class I family of cytokines and is closely related to IL–2 and IL–15. Some cancer patients have shown significant response to administration of IL–2. However, IL–2 has also been associated with severe toxicity leading to a variety of undesirable side effects. This invention attempts to resolve the toxicity concerns and presents a new therapy for cancer prevention and treatment.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 12, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04–1021 Filed 1–15–04; 8:45 am]

BILLING CODE 4140–01–P